|
所属 |
医学部 医学科 感覚運動医学講座皮膚科学分野 |
|
職名 |
教授 |
|
関連SDGs |
|
論文 【 表示 ／ 非表示 】
-
Watanabe T, Omura G, Mori T, Yoshimoto S, Ogata D
Auris, nasus, larynx 2026年8月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Auris Nasus Larynx
Immune checkpoint inhibitor (ICI) therapy may be accompanied by immune-related adverse events (irAEs). Severe irAEs frequently require immunosuppressive treatment with high-dose corticosteroids and, in refractory cases, additional agents such as infliximab. Under these circumstances, patients may become susceptible to opportunistic infections, including cytomegalovirus (CMV), which can present with clinical features closely resembling irAEs. We report the case of a 79-year-old man with malignant melanoma of the sphenoid sinus who was treated using nivolumab and ipilimumab. He developed immune-related colitis, requiring corticosteroid and infliximab treatment. Subsequently, he presented with severe pharyngeal pain and extensive oral and pharyngeal mucosal erosions, which were initially suspected to represent irAE-related mucositis. However, the lesions did not improve despite corticosteroid re-escalation. CMV antigenemia increased over time, and biopsy of the buccal mucosa confirmed CMV mucositis by immunohistochemistry. Intravenous ganciclovir led to marked clinical and virological improvement, allowing resumption of oral intake. Therefore, CMV mucositis can mimic an irAE during ICI therapy, and the risk of opportunistic infection in this setting arises primarily from immunosuppressive treatment for irAEs rather than from ICIs themselves. When severe mucosal lesions are persistent or refractory to corticosteroid escalation, clinicians should consider opportunistic infections and pursue prompt tissue evaluation for definitive diagnosis.
-
Komori T, Nakano E, Kiniwa Y, Mori S, Yamamoto S, Kato H, Yoshikawa S, Yoshino K, Aoki M, Takenouchi T, Maeda T, Yoshino K, Ohe S, Nakama K, Ishikawa H, Nakamura Y, Takai T, Ito T, Kitagawa H, Kokubu H, Hatta N, Funakoshi T, Hoashi T, Suyama T, Fujiwara S, Masuzawa M, Uchi H, Miyagawa T, Kado S, Yamamoto Y, Asai J, Kato J, Maeda T, Baba N, Kato Y, Oashi K, Maekawa T, Jinnai S, Nishizawa A, Kagoyama K, Otsuka A, Nishihara K, Ogata D, Namikawa K, Nakamura Y, Matsushita S
The Journal of dermatology 53 ( 8 ) 1124 - 1132 2026年8月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Dermatology
Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN-β (adj-IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III NAM. We analyzed 282 Japanese patients treated at 42 institutions between 2014 and 2024. Recurrence–free survival (RFS) and distant metastasis–free survival (DMFS) were co-primary outcomes, and overall survival (OS) was a secondary outcome. Survival outcomes were assessed using Kaplan–Meier analyses and Cox multivariable proportional hazards models. To minimize the differences of baseline characteristics between the two groups, propensity score matching (PSM) was applied. In multivariable Cox analyses, adj-IFN showed improved RFS (HR 0.67, 95% CI 0.45–0.998, p = 0.049), while no statistically significant benefits were observed for DMFS (HR 0.66, 95% CI 0.42–1.01, p = 0.06) or OS (HR 0.85, 95% CI 0.54–1.35, p = 0.50) compared with OBS. After PSM (71 patients per group), survival outcomes were comparable between the two groups, with no statistical significance in RFS (HR 0.71, 95% CI 0.45–1.12, p = 0.14), DMFS (HR 0.73, 95% CI 0.44–1.20, p = 0.22), or OS (HR 1.01, 95% CI 0.58–1.78, p = 0.96). In conclusion, no significant survival advantage of adj-IFN over observation was demonstrated in the matched cohort. Although a borderline association with improved RFS was observed in the overall cohort, this finding did not translate into consistent benefit across endpoints. Further prospective evidence, including the final results of the randomized phase III trial (JCOG1309, J-FERON), is required to clarify the clinical role of adj-IFN in NAM.
-
皮心伝心 出会いを大切に 査読あり
緒方 大
皮膚病診療 48 ( 7 ) 627 - 627 2026年7月
-
巻頭言 おかれた場所で咲く 査読あり
緒方 大
皮膚科の臨床 68 ( 4 ) 393 - 394 2026年4月
-
Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605). 査読あり
Oashi K, Ogata D, Yokoyama M, Sano Y, Fukuda H, Hiura A, Nakamura Y, Uehara J, Takahashi A, Namikawa K, Mori S, Nakano E, Maeda T, Miyagawa T, Yoshino K, Funakoshi T, Kiniwa Y, Nakagawa T, Shibayama Y, Uchi H, Maeda T, Muto I, Maruyama A, Takenouchi T, Hatta N, Yamazaki N
The British journal of dermatology 2026年3月
科研費（文科省・学振・厚労省）獲得実績 【 表示 ／ 非表示 】
-
神経皮膚症候群および色素性乾皮症・ポルフィリン症の学際的診療体制に基づく医療 最適化と患者 QOL 向上のための研究
研究課題/領域番号：23FC1037 2023年04月 - 2026年03月
厚生労働省 厚生科研 難治性疾患政策研究事業
担当区分：研究分担者
-
悪性黒色腫におけるALDH2遺伝子多型の発症と予後に関する影響の解明
研究課題/領域番号：21K16218 2021年04月 - 2027年03月
独立行政法人日本学術振興会 科学研究費基金 若手研究
担当区分：研究代表者